You are here: Industry Insights > Roche

News List

Roche to buy Ignyta for $1.7 billion pharmatimes
January 03, 2018
Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines.
Roche to Acquire Ignyta in $1.7B Deal contractpharma
December 28, 2017
Roche has entered an agreement to acquire Ignyta, Inc., a U.S. based pharmaceutical company focused on developing cancer therapies, for $1.7 billion. The acquisition expands Roche’s oncology portfolio globally.
Roche and Ignyta signs merger agreement biospectrumasia
December 26, 2017
The merger agreement has been unanimously approved by the boards of Ignyta and Roche
Roche boosts oncology portfolio with $1.7bn acquisition pharmafile
December 25, 2017
Roche has announced that it will buy Ignyta, a San Diego-based biotech that has a pipeline of oncology drugs, for $1.7 billion.
Roche Does Last-Minute Christmas Shopping, Drops $1.7 Billion on San Diego Biotech biospace
December 25, 2017
Basel, Switzerland-based Roche got in some last-minute Christmas shopping, shelling out $1.7 billion for San Diego’s Ignyta.
Horizon expands agreement with Roche Diagnostics pharmatimes
December 19, 2017
Cambridge, UK-based Horizon Discovery has expanded its relationship with Roche Diagnostics with a new agreement to assist in the development of immunohistochemistry (IHC) assays.
Roche announces Phase III study results for the treatment of people with advanced kidney cancer biospectrumasia
December 12, 2017
IMmotion151 is the second successive positive Phase III study of Tecentriq that includes an Avastin combination component as an initial treatment
Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibito roche
December 11, 2017
Newly approved Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents as prophylaxis or on-demand
Roche Tecentriq combo effective, but is it enough? pharmafile
December 11, 2017
When Roche announced that its combination treatment of Tecentriq, alongside its own drug Avastin and chemotherapy, successfully extended progression-free survival in advanced NSCLC – the reaction was positive but it needs quantifying, by how much?
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemothera roche
December 08, 2017
First Phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival as an initial treatment in advanced non-squamous non-small-cell lung cancer (NSCLC)

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page